Stock Events

Stock Events

Ceryvyn Therapeutics 

$0.015000
21
+$0.00+0%Monday 19:32

Statistics

Day High
0.015
Day Low
0.015
52W High
3.41
52W Low
0.002
Volume
100
Avg. Volume
10,082
Mkt Cap
20.52M
P/E Ratio
0.02
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Feb 2005
$0.13
Oct 2004
$0.10
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Aug 31Expected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.19
-0.07
0.06
0.18
Expected EPS
0
Actual EPS
0

Financials

33,044,500%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1,000Revenue
330.45MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. develops treatments for eye diseases, including Eylea, a direct competitor to Opthea's OPT-302 for wet AMD.
Regenxbio
RGNX
Mkt Cap475.29M
REGENXBIO Inc. works on gene therapies for retinal diseases, competing in the same therapeutic area as Opthea.
Bausch Health Companies
BHC
Mkt Cap3.07B
Bausch Health Companies Inc., through its subsidiary Bausch + Lomb, develops products for eye health, including treatments for AMD.
Novartis
NVSEF
Mkt Cap293.18B
Novartis AG, a major player in eye care, markets Lucentis for AMD, directly competing with Opthea's products.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. acquired Allergan, which has a portfolio of eye care products, including treatments for retinal diseases.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG offers Lucentis in some markets and is involved in the development of other drugs for eye diseases.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has investments in treatments for eye diseases, including AMD, positioning them as a competitor in the same field.
Biogen
BIIB
Mkt Cap37.49B
Biogen Inc. has shown interest in expanding its portfolio to include treatments for eye diseases, potentially competing with Opthea.
Novartis
NVS
Mkt Cap303.67B
Novartis International AG is a leading company in eye care, directly competing with Opthea in the AMD treatment market.

About

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Show More
CEO
Jeremy Max Levin Ba Zoology Dphil Mb Bchir
Employees
10
Country
Australia
ISIN
US68386J2087
WKN
000A2QEW7

Listings

AU
AU
CYV.AU
F
DE
UKJ0.F
MU
DE
UKJ2.MU
OTC Link
US
CYVNY

0 Comments

Share your thoughts

FAQs

What is Ceryvyn Therapeutics stock price today?▼
The current price of CYVNY is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Ceryvyn Therapeutics stock price performance more closely on the chart.
What is Ceryvyn Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Ceryvyn Therapeutics stocks are traded under the ticker CYVNY.
Is Ceryvyn Therapeutics stock price growing?▼
CYVNY stock has fallen by -34.78% compared to the previous week, the month change is a -34.78% fall, over the last year Ceryvyn Therapeutics has showed a -99.56% decrease.
What is Ceryvyn Therapeutics market cap?▼
Today Ceryvyn Therapeutics has the market capitalization of 20.52M
When is the next Ceryvyn Therapeutics earnings date?▼
Ceryvyn Therapeutics is going to release the next earnings report on February 23, 2027.
What were Ceryvyn Therapeutics earnings last quarter?▼
CYVNY earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ceryvyn Therapeutics revenue for the last year?▼
Ceryvyn Therapeutics revenue for the last year amounts to 1,000 USD.
What is Ceryvyn Therapeutics net income for the last year?▼
CYVNY net income for the last year is 330.45M USD.
How many employees does Ceryvyn Therapeutics have?▼
As of November 3, 2026, the company has 10 employees.
In which sector is Ceryvyn Therapeutics located?▼
Ceryvyn Therapeutics operates in the Health & Wellness sector.
When did Ceryvyn Therapeutics complete a stock split?▼
Ceryvyn Therapeutics has not had any recent stock splits.
Where is Ceryvyn Therapeutics headquartered?▼
Ceryvyn Therapeutics is headquartered in Hawthorn East, Australia.